Alveus Therapeutics Inc

Alveus Therapeutics Inc is building a portfolio of next-generation therapeutics for metabolic conditions. The company is led by world-leading experts in cardiometabolic drug discovery, clinical development, and manufacturing.

The lead asset, currently in Phase 2 clinical trials, has a dual-acting mechanism designed to go beyond the limitations of existing therapies. While recent pharmaceutical advancements have transformed the ability to induce weight loss, many challenges remain – including lack of adherence, significant treatment burden, quality of weight loss, overall cardiometabolic health, and long-term weight maintenance. Alveus’ approach aims to deliver meaningful improvements in these critical areas.

Beyond the lead program, Alveus is advancing a robust pipeline of highly differentiated small molecules, peptides, and antibodies across multiple indications. The portfolio strategy is built on a triangulation of genetic analysis, deep biological understanding, and empirical data—focusing on modalities with significantly less competition than the current development landscape.